27252904|t|Comparison of the Effects of Subcutaneous Versus Continuous Infusion of Heparin on Key Inflammatory Parameters Following Sepsis
27252904|a|Sepsis is the result of the interaction between inflammatory mediators and coagulation pathway. Unfractionated heparin may play a role as an anti-inflammatory agent beyond its anticoagulatory effect in sepsis. As a result, it may cause reduction in organ failure rate in patients with sepsis due to its impact on both inflammatory and coagulation process. The aim of this study was to evaluate the anti-inflammatory effects of heparin in sepsis. Plasma plasminogen activator inhibitor-1 (PAI-1) as an inflammatory mediator and urinary necoutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney injury were investigated. This prospective, randomized controlled trial was conducted in a 32- bed intensive care unit. Thirty patients with sepsis were randomized to receive heparin infusion of 500 units/hour or 5000 units of heparin three times a day, subcutaneously. The plasma level of PAI-1 and urinary level of NGAL were determined at day 0, 2 and 7. The infusion group had a lower plasma PAI-1 level compared to the subcutaneous group at day 7 (11.3 ± 1.6 vs. 16.5 ± 4.2; P = 0.003). The urinary NGAL level was lower in the infusion group at day 2 (131.3 ± 11.9 vs. 151.2 ± 20.6; P = 0.014); however, at day 7 the NGAL level was decreased in the subcutaneous group as much as the infusion group and there was no significant difference between the two groups. There was no significant difference in the acute physiology and chronic health evaluation (APACHE) II and sequential organ failure assessment (SOFA) scores between the two groups at day 0, 2 and 7. Low-dose heparin infusion compared to subcutaneous heparin can decrease the plasma PAI-1 and urinary NGAL levels more rapidly. It can be related to anti-inflammatory effects of heparin, which may be more prominent in infusion route.
27252904	0	10	Comparison	T052	C1707455
27252904	18	28	Effects of	T080	C1704420
27252904	29	41	Subcutaneous	T061	C0576773
27252904	49	68	Continuous Infusion	T061	C0444889
27252904	72	79	Heparin	T109,T121,T123	C0019134
27252904	83	99	Key Inflammatory	T169	C0333348
27252904	100	110	Parameters	T077	C0549193
27252904	111	120	Following	T079	C0332282
27252904	121	127	Sepsis	T047	C0243026
27252904	128	134	Sepsis	T047	C0243026
27252904	142	148	result	T169	C1274040
27252904	156	167	interaction	T169	C1704675
27252904	176	198	inflammatory mediators	T121	C0243042
27252904	203	222	coagulation pathway	T044	C1704259
27252904	224	246	Unfractionated heparin	T121	C2825026
27252904	258	262	role	T077	C1705810
27252904	269	292	anti-inflammatory agent	T121	C0003209
27252904	304	326	anticoagulatory effect	T080	C1280500
27252904	330	336	sepsis	T047	C0243026
27252904	343	349	result	T169	C1274040
27252904	364	373	reduction	T080	C0392756
27252904	377	390	organ failure	T046	C0026766
27252904	391	395	rate	T081	C1521828
27252904	399	407	patients	T101	C0030705
27252904	413	419	sepsis	T047	C0243026
27252904	431	437	impact	T080	C4049986
27252904	446	458	inflammatory	T169	C0333348
27252904	463	482	coagulation process	T039	C1328723
27252904	488	491	aim	T078	C1947946
27252904	500	505	study	T062	C0681814
27252904	513	521	evaluate	T058	C0184514
27252904	526	551	anti-inflammatory effects	T080	C1515999
27252904	555	562	heparin	T109,T121,T123	C0019134
27252904	566	572	sepsis	T047	C0243026
27252904	574	580	Plasma	T031	C0032105
27252904	581	614	plasminogen activator inhibitor-1	T116,T123	C0030190
27252904	616	621	PAI-1	T116,T123	C0030190
27252904	629	650	inflammatory mediator	T121	C0243042
27252904	655	662	urinary	T080	C1524119
27252904	663	707	necoutrophil gelatinase-associated lipocalin	T116,T123	C2347341
27252904	709	713	NGAL	T116,T123	C2347341
27252904	720	726	marker	T201	C0005516
27252904	730	743	kidney injury	T037	C0160420
27252904	749	761	investigated	T169	C1292732
27252904	768	779	prospective	T062	C0033522
27252904	781	808	randomized controlled trial	T062	C0206035
27252904	832	835	bed	T082	C1547114
27252904	836	855	intensive care unit	T073,T093	C0021708
27252904	864	872	patients	T101	C0030705
27252904	878	884	sepsis	T047	C0243026
27252904	890	900	randomized	T062	C0034656
27252904	904	911	receive	T080	C1514756
27252904	912	919	heparin	T109,T121,T123	C0019134
27252904	920	928	infusion	T169	C1827465
27252904	936	946	units/hour	T081	C0456685
27252904	955	960	units	T081	C1519795
27252904	964	971	heparin	T109,T121,T123	C0019134
27252904	972	989	three times a day	T079	C0556984
27252904	991	1005	subcutaneously	T033	C1736929
27252904	1011	1017	plasma	T031	C0032105
27252904	1018	1023	level	T080	C0441889
27252904	1027	1032	PAI-1	T116,T123	C0030190
27252904	1037	1044	urinary	T080	C1524119
27252904	1045	1050	level	T080	C0441889
27252904	1054	1058	NGAL	T116,T123	C2347341
27252904	1078	1083	day 0	T033	C0243095
27252904	1085	1086	2	T033	C3842676
27252904	1091	1092	7	T033	C3842672
27252904	1098	1106	infusion	T169	C1827465
27252904	1107	1112	group	T078	C0441833
27252904	1119	1124	lower	T082	C0441994
27252904	1125	1131	plasma	T031	C0032105
27252904	1132	1137	PAI-1	T116,T123	C0030190
27252904	1138	1143	level	T080	C0441889
27252904	1144	1152	compared	T052	C1707455
27252904	1160	1178	subcutaneous group	T078	C0441833
27252904	1182	1187	day 7	T033	C3842672
27252904	1232	1239	urinary	T080	C1524119
27252904	1240	1244	NGAL	T116,T123	C2347341
27252904	1245	1250	level	T080	C0441889
27252904	1255	1260	lower	T082	C0441994
27252904	1268	1276	infusion	T169	C1827465
27252904	1277	1282	group	T078	C0441833
27252904	1286	1291	day 2	T033	C3842676
27252904	1348	1353	day 7	T033	C3842672
27252904	1358	1362	NGAL	T116,T123	C2347341
27252904	1363	1368	level	T080	C0441889
27252904	1373	1382	decreased	T081	C0205216
27252904	1390	1408	subcutaneous group	T078	C0441833
27252904	1424	1432	infusion	T169	C1827465
27252904	1433	1438	group	T078	C0441833
27252904	1453	1467	no significant	T080	C0205556
27252904	1468	1478	difference	T080	C1705242
27252904	1495	1501	groups	T078	C0441833
27252904	1513	1527	no significant	T080	C0205556
27252904	1528	1538	difference	T080	C1705242
27252904	1546	1604	acute physiology and chronic health evaluation (APACHE) II	T060	C0489438
27252904	1609	1658	sequential organ failure assessment (SOFA) scores	T033	C3494459
27252904	1675	1681	groups	T078	C0441833
27252904	1685	1690	day 0	T033	C0243095
27252904	1692	1693	2	T033	C3842676
27252904	1698	1699	7	T033	C3842672
27252904	1701	1709	Low-dose	T081	C0445550
27252904	1710	1717	heparin	T109,T121,T123	C0019134
27252904	1718	1726	infusion	T169	C1827465
27252904	1727	1735	compared	T052	C1707455
27252904	1739	1751	subcutaneous	T082	C0443315
27252904	1752	1759	heparin	T109,T121,T123	C0019134
27252904	1764	1772	decrease	T081	C0547047
27252904	1777	1783	plasma	T031	C0032105
27252904	1784	1789	PAI-1	T116,T123	C0030190
27252904	1794	1801	urinary	T080	C1524119
27252904	1802	1806	NGAL	T116,T123	C2347341
27252904	1807	1813	levels	T080	C0441889
27252904	1819	1826	rapidly	T080	C0456962
27252904	1838	1845	related	T080	C0439849
27252904	1849	1874	anti-inflammatory effects	T080	C1515999
27252904	1878	1885	heparin	T109,T121,T123	C0019134
27252904	1905	1914	prominent	T080	C0205402
27252904	1918	1932	infusion route	T169	C1827465